# Immunotherapy and Immune Responses

**Type:** Topics  
**Canonical URL:** https://scholariq.org/topics/immunotherapy-and-immune-responses/

## Facts

| Field | Value |
| --- | --- |
| Description | This cluster of papers focuses on the immunobiology of dendritic cells, their role in antigen presentation, modulation of immunity, and their potential applications in cancer immunotherapy and vaccine development. The research covers topics such as dendritic cell subsets, tumor antigen presentation, immune tolerance, and the use of adjuvants to enhance immune responses. |
| Domain | Life Sciences |
| Field | Immunology and Microbiology |
| OpenAlex ID | t10580 |
| Works | 589 |

## Topic papers all

Showing 15 of 589.

- [Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer](https://scholariq.org/papers/safety-activity-and-immune-correlates-of-anti-pd-1-antibody-in-cancer/)
- [Nivolumab versus Docetaxel in Advanced Nonsquamous Non–Small-Cell Lung Cancer](https://scholariq.org/papers/nivolumab-versus-docetaxel-in-advanced-nonsquamous-non-small-cell-lung-cancer/)
- [Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced Cancer](https://scholariq.org/papers/safety-and-activity-of-anti-pd-l1-antibody-in-patients-with-advanced-cancer/)
- [Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial](https://scholariq.org/papers/atezolizumab-versus-docetaxel-in-patients-with-previously-treated-non-small-cell/)
- [The evaluation of tumor-infiltrating lymphocytes (TILs) in breast cancer: recommendations by an International TILs Working Group 2014](https://scholariq.org/papers/the-evaluation-of-tumor-infiltrating-lymphocytes-tils-in-breast-cancer/)
- [Clonal neoantigens elicit T cell immunoreactivity and sensitivity to immune checkpoint blockade](https://scholariq.org/papers/clonal-neoantigens-elicit-t-cell-immunoreactivity-and-sensitivity-to-immune/)
- [Genomic correlates of response to CTLA-4 blockade in metastatic melanoma](https://scholariq.org/papers/genomic-correlates-of-response-to-ctla-4-blockade-in-metastatic-melanoma/)
- [Phase I Study of Single-Agent Anti–Programmed Death-1 (MDX-1106) in Refractory Solid Tumors: Safety, Clinical Activity, Pharmacodynamics, and Immunologic Correlates](https://scholariq.org/papers/phase-i-study-of-single-agent-anti-programmed-death-1-mdx-1106-in-refractory/)
- [Nivolumab plus Ipilimumab in Advanced Non–Small-Cell Lung Cancer](https://scholariq.org/papers/nivolumab-plus-ipilimumab-in-advanced-non-small-cell-lung-cancer/)
- [Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial](https://scholariq.org/papers/nivolumab-versus-chemotherapy-in-patients-with-advanced-melanoma-who-progressed/)
- [Cancer Regression in Patients After Transfer of Genetically Engineered Lymphocytes](https://scholariq.org/papers/cancer-regression-in-patients-after-transfer-of-genetically-engineered/)
- [PD-L1 Expression as a Predictive Biomarker in Cancer Immunotherapy](https://scholariq.org/papers/pd-l1-expression-as-a-predictive-biomarker-in-cancer-immunotherapy/)
- [Use of Tumor-Infiltrating Lymphocytes and Interleukin-2 in the Immunotherapy of Patients with Metastatic Melanoma](https://scholariq.org/papers/use-of-tumor-infiltrating-lymphocytes-and-interleukin-2-in-the-immunotherapy-of/)
- [Neoadjuvant PD-1 Blockade in Resectable Lung Cancer](https://scholariq.org/papers/neoadjuvant-pd-1-blockade-in-resectable-lung-cancer/)
- [Tumour-infiltrating lymphocytes and prognosis in different subtypes of breast cancer: a pooled analysis of 3771 patients treated with neoadjuvant therapy](https://scholariq.org/papers/tumour-infiltrating-lymphocytes-and-prognosis-in-different-subtypes-of-breast/)

## Topic primary papers

Showing 15 of 114.

- [Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma](https://scholariq.org/papers/immunologic-and-therapeutic-evaluation-of-a-synthetic-peptide-vaccine-for-the/)
- [Induction of Protective IgA by Intestinal Dendritic Cells Carrying Commensal Bacteria](https://scholariq.org/papers/induction-of-protective-iga-by-intestinal-dendritic-cells-carrying-commensal/)
- [CD40-CD40 ligand](https://scholariq.org/papers/cd40-cd40-ligand/)
- [Allele-Specific HLA Loss and Immune Escape in Lung Cancer Evolution](https://scholariq.org/papers/allele-specific-hla-loss-and-immune-escape-in-lung-cancer-evolution/)
- [Activation of human dendritic cells through CD40 cross-linking.](https://scholariq.org/papers/activation-of-human-dendritic-cells-through-cd40-cross-linking/)
- [Patient HLA class I genotype influences cancer response to checkpoint blockade immunotherapy](https://scholariq.org/papers/patient-hla-class-i-genotype-influences-cancer-response-to-checkpoint-blockade/)
- [Cancer cell–autonomous contribution of type I interferon signaling to the efficacy of chemotherapy](https://scholariq.org/papers/cancer-cell-autonomous-contribution-of-type-i-interferon-signaling-to-the/)
- [Long-Term Survival for Patients With Non–Small-Cell Lung Cancer With Intratumoral Lymphoid Structures](https://scholariq.org/papers/long-term-survival-for-patients-with-non-small-cell-lung-cancer-with/)
- [A conserved dendritic-cell regulatory program limits antitumour immunity](https://scholariq.org/papers/a-conserved-dendritic-cell-regulatory-program-limits-antitumour-immunity/)
- [Vascular Endothelial Growth Factor Inhibits the Development of Dendritic Cells and Dramatically Affects the Differentiation of Multiple Hematopoietic Lineages In Vivo](https://scholariq.org/papers/vascular-endothelial-growth-factor-inhibits-the-development-of-dendritic-cells/)
- [Human IL-10 is produced by both type 1 helper (Th1) and type 2 helper (Th2) T cell clones and inhibits their antigen-specific proliferation and cytokine production](https://scholariq.org/papers/human-il-10-is-produced-by-both-type-1-helper-th1-and-type-2-helper-th2-t-cell/)
- [Dynamics and Function of Langerhans Cells In Vivo](https://scholariq.org/papers/dynamics-and-function-of-langerhans-cells-in-vivo/)
- [gp100 Peptide Vaccine and Interleukin-2 in Patients with Advanced Melanoma](https://scholariq.org/papers/gp100-peptide-vaccine-and-interleukin-2-in-patients-with-advanced-melanoma/)
- [Vascular Endothelial Growth Factor Inhibits the Development of Dendritic Cells and Dramatically Affects the Differentiation of Multiple Hematopoietic Lineages In Vivo](https://scholariq.org/papers/vascular-endothelial-growth-factor-inhibits-the-development-of-dendritic-cells-2/)
- [Lipid accumulation and dendritic cell dysfunction in cancer](https://scholariq.org/papers/lipid-accumulation-and-dendritic-cell-dysfunction-in-cancer/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.